ANI Pharmaceuticals, Inc.
ANIP
$63.26
$1.863.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 44.75% | 12.52% | 18.44% | 28.70% | 39.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.75% | 12.52% | 18.44% | 28.70% | 39.71% |
| Cost of Revenue | 50.28% | 31.13% | 36.45% | 30.36% | 47.06% |
| Gross Profit | 40.98% | 1.83% | 8.19% | 27.79% | 35.11% |
| SG&A Expenses | 56.36% | 67.29% | 27.51% | 31.68% | 86.91% |
| Depreciation & Amortization | 48.74% | 3.56% | 0.05% | -0.10% | 4.90% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.77% | 36.75% | 25.22% | 29.09% | 54.03% |
| Operating Income | -82.45% | -170.77% | -33.57% | 25.60% | -39.56% |
| Income Before Tax | -1,553.22% | -373.63% | -143.57% | 1,070.21% | 116.53% |
| Income Tax Expenses | -1,575.96% | -566.71% | 100.00% | 881.82% | 85.99% |
| Earnings from Continuing Operations | -989.70% | -343.12% | -136.62% | 1,165.25% | 127.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -989.70% | -343.12% | -136.62% | 1,165.25% | 127.22% |
| EBIT | -82.45% | -170.77% | -33.57% | 25.60% | -39.56% |
| EBITDA | 0.94% | -84.14% | -16.01% | 11.45% | -20.27% |
| EPS Basic | -1,592.66% | -376.67% | -115.50% | 1,392.87% | 112.92% |
| Normalized Basic EPS | -295.54% | -271.26% | -39.08% | 110.17% | -72.37% |
| EPS Diluted | -1,604.93% | -380.73% | -115.86% | 1,381.15% | 112.47% |
| Normalized Diluted EPS | -297.80% | -273.42% | -38.50% | 108.45% | -72.69% |
| Average Basic Shares Outstanding | 2.34% | 2.76% | 9.23% | 16.51% | 16.40% |
| Average Diluted Shares Outstanding | 1.19% | 1.46% | 8.21% | 17.49% | 17.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.11% | -1.41% | -3.73% | -0.92% | 4.66% |
